Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination

Neurology

Volumn 52, Issue 3, 1999, Pages 599-606

  Sailer, M ^a   O'Riordan, J I ^a   Thompson, A J ^a   Kingsley, D P ^a   MacManus, D G ^a   McDonald, W I ^a,b   Miller, D H ^a,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN SCINTISCANNING; DIAGNOSTIC VALUE; DISEASE SEVERITY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033051647     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.3.599     Document Type: Article

References (38)

1. Miller DH, Grossmann RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
2. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-185.
3. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-667.
4. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
5. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994;344:298-301.
6. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49: 351-357.
7. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258.
8. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994;36(suppl):91-94.
9. Mammi S, Filippi M, Martinelli V, et al. Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis. Acta Neurol Scand 1996;94:93-96.
10. Frederiksen JL, Larsson HB, Jensen C. Serial gadolinium-enhanced MRI in untreated patients with acute optic neuritis: implications for natural history. Acta Neurol Scand 1997;96: 22-27.
11. Paty DW. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci 1988; 15:266-272.
12. Ormerod IE, Miller DH, McDonald WI, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions: a quantitative study. Brain 1987;110: 1579-1616.
13. Jacobs L, Kinkel PR, Kinkel WR. Silent brain lesions in patients with isolated idiopathic optic neuritis: a clinical and nuclear magnetic resonance imaging study. Arch Neurol 1986; 43:452-455.
14. Miller DH, McDonald WI, Blumhardt LD, et al. Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. Ann Neurol 1987;22:714-723.
15. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain 1993;116:135-146.
16. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI. Brain magnetic resonance imaging in acute optic neuritis: experience of the Optic Neuritis Study Group. Arch Neurol 1993;50:841-846.
17. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994; 44:635-641.
18. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain 1998;121:495-503.
19. Miller DH, Ormerod IE, McDonald WI, et al. The early risk of multiple sclerosis after optic neuritis. J Neurol Neurosurg Psychiatry 1988;51:1569-1571.
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
22. Plummer DL. DispImage: a display and analysis tool for medical images. Revista di Neuroradiologica 1992;5:489-495.
23. Grimaud J, Lai M, Thorpe JW, et al. Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imaging 1996;14: 495-505.
24. Wicks DA, Barker GJ, Tofts PS. Correction of intensity non-uniformity in MR images of any orientation. Magn Reson Imaging 1993;11:183-196.
25. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991;114: 1045-1056.
26. Thompson AJ, Kermode AG, MacManus DG, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990;300:631-634.
27. Koopmans RA, Li DK, Grochowski E, Cutler PJ, Paty DW. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. Ann Neurol 1989;25:74-81.
28. Wang L, Lai HM, Thompson AJ, Miller DH. Survey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load. J Neurol Neurosurg Psychiatry 1997;63:452-455.
29. Filippi M, Horsfield MA, Tofts PS, Barkhof F, Thompson AJ, Miller DH. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118: 1601-1612.
30. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255-260.
31. Brück W, Bitsch A, Kolenda H, Brück Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging with lesion pathology. Ann Neurol 1997;42:783-793.
32. Truyen L, Gheuens J, Parizel PM, Van de VF, Martin JJ. Long term follow-up of multiple sclerosis by standardized, non-contrast-enhanced magnetic resonance imaging. J Neurol Sci 1991;106:35-40.
33. Filippi M, van Waesberghe JH, Horsfield MA, et al. Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. Neurology 1997;49:371-377.
34. van Walderveen WM, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45:1684-1690.
35. Silver NC, Barker GJ, Losseff NA, et al. Magnetisation transfer ratio measurement in the cervical spinal cord: a preliminary study in multiple sclerosis. Neuroradiology 1997;39:441-445.
36. Filippi M, Comi G. Magnetization transfer ratio changes in a symptomatic lesion of a patient at presentation with possible multiple sclerosis. J Neurol Sci 1997;151:79-81.
37. Davies SE, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995;64:742-748.
38. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119: 2009-2019.